Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12730636 | 0.89 | HCAR2 (0.51) | HCAR2MAOBCA2CA4KDM4E | |
| SCHEMBL1655775 | 0.87 | HCAR2 (0.49) | HCAR2MAOBCA12CA1CA2 | |
| SCHEMBL1655821 | 0.87 | HCAR2 (0.49) | HCAR2MAOBCA2NPC1RAB9A | |
| SCHEMBL12730608 | 0.86 | HCAR2 (0.48) | HCAR2MAOBCA2CNR1 | |
| SCHEMBL1655365 | 0.86 | HCAR2 (0.48) | HCAR2MAOBCA12CA1CA2 | |
| SCHEMBL11745645 | 0.84 | HCAR2 (0.61) | HCAR2CA12NPC1RAB9ACYP1A2 | |
| SCHEMBL9422317 | 0.83 | HCAR2 (0.65) | HCAR2MAOBCA1CA2CYP1A2 | |
| Acipimox SCHEMBL11743417 | 0.79 | HCAR2 (0.79) | HCAR2MAOBCYP1A2TSHRNFKB1 | |
| SCHEMBL1656465 | 0.79 | HCAR2 (0.49) | HCAR2CA12CA1CA2 | |
| Acipimox SCHEMBL28438037 | 0.78 | HCAR2 (0.77) | HCAR2MAOBCYP1A2TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011044136-A1 | FATTY ACID ACIPIMOX DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044136-A1 | FATTY ACID ACIPIMOX DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20110082156-A1 | FATTY ACID ACIPIMOX DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110082156-A1 | FATTY ACID ACIPIMOX DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082156-A1 | FATTY ACID ACIPIMOX DERIVATIVES AND THEIR USES | ACOX3, ACOX1, PAOX | HCAR2 122/4885MAOB 1010/4885CA12 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.